
Opinion|Videos|January 1, 2025
Discussing Seladelpar as a Potential Therapeutic for PBC
Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Seladelpar has been studied extensively, with the
RESPONSE trial serving as one of its landmark studies. What are the key efficacy findings from this trial?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
2
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
3
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
4
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
5